Prestige Consumer Healthcare Sees FY25 Revenue Growth ~1%, EPS $4.40-$4.46 vs $4.62 Est.
$PBH
Biotechnology: Pharmaceutical Preparations
Health Care
Prestige Consumer Healthcare Sees FY25 Revenue Growth ~1%, EPS $4.40-$4.46 vs $4.62 Est.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/21/2024 | $65.00 → $93.00 | Neutral → Buy | DA Davidson |
| 11/17/2022 | $71.00 | Buy | Canaccord Genuity |
| 5/10/2022 | $65.00 → $70.00 | Hold → Buy | Jefferies |
| 5/9/2022 | $63.00 | Perform → Outperform | Oppenheimer |
| 3/11/2022 | $156.00 → $142.00 | Outperform | BMO Capital |
| 11/15/2021 | $61.00 → $63.00 | Neutral | DA Davidson |
| 11/5/2021 | $123.00 → $126.00 | Sector Perform | RBC Capital |
| 8/6/2021 | $107.00 → $123.00 | Sector Perform | RBC Capital |
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Oppenheimer analyst Brian Nagel upgraded the rating for NIKE, Inc. (NYSE:NKE) from Perform to Outperform, while raising the price target from $110 to $120. Nike shares gained 0.8% to close at $95.57 on Thursday. See how other analysts view this stock. Morgan Stanley analyst Carlos De Alba upgraded Alcoa Corporation (NYSE:AA) from Equal-Weight to Overweight and boosted the price target from $36.5 to $50. Alcoa shares gained 4% to close at $38.98 on Thursday. See how other analysts view
DA Davidson analyst Linda Bolton Weiser upgrades Prestige Consumer (NYSE:PBH) from Neutral to Buy and raises the price target from $65 to $93.
Canaccord Genuity analyst Susan Anderson maintains Prestige Consumer (NYSE:PBH) with a Buy and maintains $80 price target.
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously
Canaccord Genuity initiated coverage of Prestige Consumer with a rating of Buy and set a new price target of $71.00
Jefferies upgraded Prestige Consumer from Hold to Buy and set a new price target of $70.00 from $65.00 previously
SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
10-Q - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
10-Q - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic
Revenue of $283.8 Million in Q2, Ahead of OutlookDiluted EPS of $1.09 in Q2, Up 2% Versus Prior YearNet Cash Provided by Operating Activities of Approximately $125 Million in First Six Months, Up Approximately 13%; Reduced Debt by $75 Million and Repurchased $38 Million Shares Year-to-DateReaffirming Full-Year Fiscal 2025 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2024. "Our second quarter results exceeded our sales and earnings expectations thanks to the strength of our diverse portfolio of mark
TARRYTOWN, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 second quarter earnings release on Thursday, November 7, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes pr
TARRYTOWN, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, September 5, 2024 at 2:15 p.m. ET. All interested parties may access a live webcast of this event at www.prestigeconsumerhealthcare.com under the "Investors" section and the "Events and Presentations" tab, or by using the following link: https://ir.prestigebrands.com/events-presentations/events For those unable to participate during the live webcast, a replay option will be available on the Company's website following the event. About Prestige Consumer Healthcare Inc. Prestige Consumer Healthcar
Revenue of $283.8 Million in Q2, Ahead of OutlookDiluted EPS of $1.09 in Q2, Up 2% Versus Prior YearNet Cash Provided by Operating Activities of Approximately $125 Million in First Six Months, Up Approximately 13%; Reduced Debt by $75 Million and Repurchased $38 Million Shares Year-to-DateReaffirming Full-Year Fiscal 2025 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2024. "Our second quarter results exceeded our sales and earnings expectations thanks to the strength of our diverse portfolio of mark
TARRYTOWN, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 second quarter earnings release on Thursday, November 7, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes pr
Revenue of $267.1 Million in Q1, Ahead of Expectations, down 4.4% versus Prior YearEPS of $0.98 and Adjusted EPS of $0.90 in Q1 Compared to $1.06 in the Prior YearCash from Operations of $54.8 Million up 13.9% versus Prior Year; Reduced Debt by $35 Million and Repurchased $26 Million SharesReaffirming Full-Year Fiscal 2025 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter ended June 30, 2024. "We are pleased that our first quarter results exceeded our sales and earnings expectations. First quarter revenues were stronger than expected, primarily due